Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Mise à jour : Il y a 5 ans
Référence : NCT00432614

Femme et Homme

Extrait

The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram. The secondary objective of this study is to document clinical safety and tolerability of SR58611A in association with escitalopram.


Critère d'inclusion

  • Major Depressive Disorder


Liens